Pasi A. Jänne, MD, PhD

Medical Oncology

Pasi A. Jänne, MD, PhD

Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He is the director of the Lowe Center for Thoracic Oncology and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.

View Full Profile

Related Videos

Pasi Jänne, MD, PhD Discusses Lung Cancer data at AACR24 Video

Pasi Jänne, MD, PhD Discusses Lung Cancer data at AACR24

Dana-Farber's Pasi Jänne, MD, PhD, reports on ctDNA with an EGFR mutation in FLAURA2 trial. The new data shows patients whose blood tested positive before therapy for tumor cell DNA with EGFR mutations stood to gain the most from combination therapy.

Lung Cancer Research at ESMO Video

Lung Cancer Research at ESMO

Dana-Farber's Pasi A. Jänne, MD, PhD, provides insight on DESTINY-Lung01 trial in lung cancer highlighted at ESMO 2021.

ASCO22: Pasi Janne, MD, PhD on lung cancer research Video

ASCO22: Pasi Janne, MD, PhD on lung cancer research

Lung cancer research at #ASCO22. Non-small cell lung cancers with KRAS mutation respond to experimental drug adagrasib which also shows activity in brain metastasis. Dana-Farber's Pasi Janne, MD, PhD, is senior author and explains more.